Shanghai Desano Pharmaceuticals Co., Ltd.

Overview

Shanghai Desano Pharmaceuticals Co., Ltd. is a leading pharmaceutical company based in China specializing in the development, production, and commercialization of generic and branded medications. The company is known for its focus on innovative drug solutions and its strong commitment towards meeting international quality standards.

Therapeutic areas

API / Drug Master Files

Shanghai Desano Pharmaceuticals Co., Ltd. holds 33 active (39 total) FDA Type II Drug Master Files — identifying it as an active-substance / API supplier. Type II DMFs are filed with the FDA to support the use of an active pharmaceutical ingredient in drug applications.

• FINERENONEActive2026-03-06
• ATOVAQUONEActive2026-02-12
• UPADACITINIBActive2026-02-01
• DOTINURADActive2025-12-24
• OMADACYCLINE TOSYLATEActive2025-12-19
• ELTROMBOPAG OLAMINEActive2025-06-16
• LUMEFANTRINEActive2024-12-30
• LETERMOVIRActive2024-11-22
• TEDIZOLID PHOSPHATEActive2024-10-11
• LASMIDITAN HEMISUCCINATEActive2024-09-05
• ISAVUCONAZONIUM SULFATEActive2024-08-27
• RILPIVIRINE HYDROCHLORIDEActive2024-02-27
• CABOTEGRAVIR SODIUMActive2022-09-14
• ELAGOLIX SODIUMActive2022-03-09
• EDOXABAN TOSYLATE MONOHYDRATEActive2021-07-09

Showing 15 of 39 Drug Master Files.

FDA compliance signals

No FDA recalls, Warning Letters, or Form 483 observations are linked to Shanghai Desano Pharmaceuticals Co., Ltd. in our records. PharmaTek screens the full directory against live FDA enforcement data.